These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1978443)

  • 1. High-dose intravenous immunoglobulins in HIV-1-infected adults with AIDS-related complex and Walter-Reed 5.
    Schrappe-Bächer M; Rasokat H; Bauer P; Bendick C; Bube FW; Degenhardt S; Fätkenheuer G; Heiniger HJ; Heitmann K; Imbach P
    Vox Sang; 1990; 59 Suppl 1():3-14. PubMed ID: 1978443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphocyte proliferation in AIDS-related complex/Walter-Reed 5 patients: response to herpes simplex virus and tuberculin antigen and mitogen during intravenous immunoglobulin treatment. The ARC-IVIG Study Group.
    Krickeberg H; Mauff G; Mertens T; Plum G; Heitmann K
    Vox Sang; 1990; 59 Suppl 1():38-43. PubMed ID: 2173282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement levels and circulating immune complexes in a controlled, longitudinal, multicentre study on effects of intravenous immunoglobulin in adults with AIDS-related complex/Walter-Reed 5. The ARC-IVIG Study Group.
    Späth PJ; Braun M; Meyer-Hänni L; Mohren D; Mauff G
    Vox Sang; 1990; 59 Suppl 1():51-8. PubMed ID: 2238575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virological examinations of patients with AIDS-related complex/Walter-Reed 5 enrolled in a double-blind placebo-controlled study with intravenous gammaglobulin administration. Prognostic value of anti-p24 determination. The ARC-IVIG Study Group.
    Mertens T; Ramon A; Kruppenbacher JP; Heitmann K; Pika U; Leyssens N; Lievens M
    Vox Sang; 1990; 59 Suppl 1():21-9. PubMed ID: 1700551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantification of complement receptor 1 on erythrocytes: follow-up of HIV-1-infected patients with AIDS-related complex/Walter-Reed 5 under treatment with intravenous immunoglobulin. The ARC-IVIG Study Group.
    Spycher MO; Späth PJ
    Vox Sang; 1990; 59 Suppl 1():44-50. PubMed ID: 2146812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular immunologic parameters in HIV-positive patients with AIDS-related complex and intravenous immunoglobulin therapy.
    Krueger GR; Ramon A; Degenhardt S; Schrappe-Bächer M; Rasokat H; Koch B; Deninger J
    Vox Sang; 1990; 59 Suppl 1():30-7. PubMed ID: 2238574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of intravenous immunoglobulins in patients with advanced HIV-1 infection. A randomized clinical study.
    Brunkhorst U; Stürner M; Willers H; Deicher H; Schedel I
    Infection; 1990; 18(2):86-90. PubMed ID: 1970552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Intravenous immunoglobulin substitution in patients with ARC and AIDS (WR 3-6)].
    Kiehl M; Stoll R; Domschke W
    Immun Infekt; 1994 Apr; 22(2):53-5. PubMed ID: 7959860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection.
    National Institute of Child Health and Human Developments Intravenous Immunoglobulin Study Group
    N Engl J Med; 1991 Jul; 325(2):73-80. PubMed ID: 1675763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Passive immunization in ARC and AIDS.
    Karpas A; Gray J; Byron N; Gilgen D; Bally V; Oates JK; Gazzard B
    Biotherapy; 1990; 2(2):159-72. PubMed ID: 2144762
    [No Abstract]   [Full Text] [Related]  

  • 11. T activation marker evaluation in ARC patients treated with AZT. Comparison with CD4+ lymphocyte count in non-progressors and progressors towards AIDS.
    Levacher M; Tallet S; Dazza MC; Dournon E; Rouveix B; Pocidalo JJ
    Clin Exp Immunol; 1990 Aug; 81(2):177-82. PubMed ID: 1696859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: a double-blind randomized trial. European-Australian Collaborative Group.
    Cooper DA; Pehrson PO; Pedersen C; Moroni M; Oksenhendler E; Rozenbaum W; Clumeck N; Faber V; Stille W; Hirschel B
    AIDS; 1993 Feb; 7(2):197-207. PubMed ID: 8096703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spectrum of immunodeficiency in HIV-1-infected patients with pulmonary tuberculosis in Zaire.
    Mukadi Y; Perriëns JH; St Louis ME; Brown C; Prignot J; Willame JC; Pouthier F; Kaboto M; Ryder RW; Portaels F
    Lancet; 1993 Jul; 342(8864):143-6. PubMed ID: 8101257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II vaccination study of recombinant peptide F46 corresponding to the HIV-1 transmembrane protein coupled with 2.4 dinitrophenyl (DNP) Ficoll.
    Schwander S; Opravil M; Lüthy R; Hanson DG; Schindler J; Dawson A; Letwin B; Dietrich M
    Infection; 1994; 22(2):86-91. PubMed ID: 7915256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017).
    Mulder JW; Cooper DA; Mathiesen L; Sandström E; Clumeck N; Gatell JM; French M; Donovan B; Gray F; Yeo JM
    AIDS; 1994 Mar; 8(3):313-21. PubMed ID: 7913326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Major histocompatibility complex class I to III allotypes in patients with AIDS-related complex/Walter-Reed 5, disseminated Kaposi's sarcoma and in normal controls. The ARC-IVIG Study Group.
    Plum G; Siebel E; Bendick C; Rasokat H; Braun M; Krickeberg H; Mauff G
    Vox Sang; 1990; 59 Suppl 1():15-20. PubMed ID: 2238573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of passive immunization in patients with the acquired immunodeficiency syndrome-related complex and acquired immunodeficiency syndrome.
    Karpas A; Hill F; Youle M; Cullen V; Gray J; Byron N; Hayhoe F; Tenant-Flowers M; Howard L; Gilgen D
    Proc Natl Acad Sci U S A; 1988 Dec; 85(23):9234-7. PubMed ID: 3194422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relation between plasma concentrations of didanosine and markers of antiviral efficacy in adults with AIDS or AIDS-related complex.
    Beltangady M; Knupp CA; Gustafson N; Barbhaiya RH; Dolin R; Seidlin M; Cooley TP; Rozencweig M
    Clin Infect Dis; 1993 Feb; 16 Suppl 1():S26-31. PubMed ID: 8093845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant alpha-2a interferon treatment in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex (ARC): clinical and immunological evaluation.
    Mezzaroma I; Avella A; Paganelli R; Ensoli B; d'Offizi G; Sirianni MC; Luzi G; Valdarchi C; Aiuti F
    Allergol Immunopathol (Madr); 1991; 19(5):201-7. PubMed ID: 1811417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.
    Fischl MA; Richman DD; Hansen N; Collier AC; Carey JT; Para MF; Hardy WD; Dolin R; Powderly WG; Allan JD
    Ann Intern Med; 1990 May; 112(10):727-37. PubMed ID: 1970466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.